PICO Portalanswers from OpenAlex & ORCID
Ken Kato
ResearcherPublications, citations & collaboration network
Ken Kato is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Ken Kato have?
PICO Portalindexed works
Ken Kato has 834 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ken Kato have?
PICO Portalcitation count
Ken Kato has 31,223 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Ken Kato?
PICO Portalh-index
Ken Kato has an h-index of 76 in OpenAlex.
What is the i10-index of Ken Kato?
PICO Portali10-index
Ken Kato has an i10-index of 321 in OpenAlex.
What is the ORCID of Ken Kato?
PICO Portalorcid
The ORCID for Ken Kato is on the source record.
What is the OpenAlex record for Ken Kato?
PICO Portalopenalex
The OpenAlex for Ken Kato is on the source record.
What are the most-cited papers on Ken Kato?
PICO Portalmost cited works
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong‐Mu Sun, Lin Shen, Manish A. Shah, Peter C. Enzinger, Antoine Adenis, Toshihiko Doi, Takashi Kojima, Jean‐Philippe Metges, Zhigang Li, Sung‐Bae Kim, Byoung Chul Cho, Wasat Mansoor, Shau-Hsuan Li, Patrapim Sunpaweravong, María Maqueda, Eray Goekkurt, Hiroki Hara, Luís Carlos Moreira Antunes, Christos Fountzilas, Akihito Tsuji, Victor Castro Oliden, Qi Liu, Sukrut Shah, Pooja Bhagia, Ken Kato
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Morihito Okada, Chen-Yuan Lin, Keisho Chìn, Shigenori Kadowaki, Myung‐Ju Ahn, Yasuo Hamamoto, Yuichiro� Doki, Chueh‐Chuan Yen, Yutaro Kubota, Sung‐Bae Kim, Chih‐Hung Hsu, Eva Holtved, Ioannis Xynos, Mamoru Kodani, Yuko Kitagawa
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima, Manish A. Shah, Kei Muro, Éric François, Antoine Adenis, Chih‐Hung Hsu, Toshihiko Doi, Toshikazu Moriwaki, Sung‐Bae Kim, Se‐Hoon Lee, Jaafar Bennouna, Ken Kato, Lin Shen, Peter C. Enzinger, Shukui Qin, Paula Ferreira, Jia Chen, Gustavo Girotto, Christelle de la Fouchardière, Hélène Senellart, Raed Moh’d Taiseer Al-Rajabi, Florian Lordick, Ruixue Wang, Shailaja Suryawanshi, Pooja Bhagia, Soonmo Peter Kang, Jean‐Philippe Metges, on behalf of the KEYNOTE-181 Investigators
Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2
Yuko Kitagawa, Takashi Uno, Tsuneo Oyama, Ken Kato, Hiroyuki Kato, Hirofumi Kawakubo, Osamu Kawamura, Motoyasu Kusano, Hiroyuki Kuwano, Hiroya Takeuchi, Yasushi Toh, Yuichiro� Doki, Yoshio Naomoto, Kenji Nemoto, Eisuke Booka, Hisahiro Matsubara, Tatsuya Miyazaki, Manabu Muto, Akio Yanagisawa, Masahiro Yoshida
Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1
Yuko Kitagawa, Takashi Uno, Tsuneo Oyama, Ken Kato, Hiroyuki Kato, Hirofumi Kawakubo, Osamu Kawamura, Motoyasu Kusano, Hiroyuki Kuwano, Hiroya Takeuchi, Yasushi Toh, Yuichiro� Doki, Yoshio Naomoto, Kenji Nemoto, Eisuke Booka, Hisahiro Matsubara, Tatsuya Miyazaki, Manabu Muto, Akio Yanagisawa, Masahiro Yoshida